DE69837118T2 - Ein Verfahren zum Screenen von Substanzen hinsichtlich ihres Effekts auf cAMP Spiegel basierend auf intrazellulärer Translokation von PKA - Google Patents
Ein Verfahren zum Screenen von Substanzen hinsichtlich ihres Effekts auf cAMP Spiegel basierend auf intrazellulärer Translokation von PKA Download PDFInfo
- Publication number
- DE69837118T2 DE69837118T2 DE69837118T DE69837118T DE69837118T2 DE 69837118 T2 DE69837118 T2 DE 69837118T2 DE 69837118 T DE69837118 T DE 69837118T DE 69837118 T DE69837118 T DE 69837118T DE 69837118 T2 DE69837118 T2 DE 69837118T2
- Authority
- DE
- Germany
- Prior art keywords
- cells
- cell
- gfp
- change
- redistribution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 130
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 title claims abstract description 15
- 239000000126 substance Substances 0.000 title claims description 35
- 230000005945 translocation Effects 0.000 title claims description 31
- 230000003834 intracellular effect Effects 0.000 title claims description 23
- 230000000694 effects Effects 0.000 title description 34
- 238000012216 screening Methods 0.000 title description 4
- 239000005090 green fluorescent protein Substances 0.000 claims abstract description 133
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims abstract description 68
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims abstract description 68
- 230000031146 intracellular signal transduction Effects 0.000 claims abstract description 18
- 238000005259 measurement Methods 0.000 claims abstract description 17
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 claims abstract description 12
- 238000002165 resonance energy transfer Methods 0.000 claims abstract description 10
- 108010048367 enhanced green fluorescent protein Proteins 0.000 claims abstract description 8
- 230000010287 polarization Effects 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 215
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 58
- 230000008859 change Effects 0.000 claims description 52
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 51
- 229920001184 polypeptide Polymers 0.000 claims description 49
- 238000003556 assay Methods 0.000 claims description 24
- 230000004044 response Effects 0.000 claims description 24
- 230000004913 activation Effects 0.000 claims description 22
- 230000001413 cellular effect Effects 0.000 claims description 21
- 238000009826 distribution Methods 0.000 claims description 21
- 230000014509 gene expression Effects 0.000 claims description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
- 238000012545 processing Methods 0.000 claims description 14
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 125000005647 linker group Chemical group 0.000 claims description 12
- 210000004962 mammalian cell Anatomy 0.000 claims description 11
- 238000004020 luminiscence type Methods 0.000 claims description 10
- 230000004071 biological effect Effects 0.000 claims description 9
- 230000003197 catalytic effect Effects 0.000 claims description 9
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 210000004899 c-terminal region Anatomy 0.000 claims description 7
- 230000008827 biological function Effects 0.000 claims description 6
- 230000002588 toxic effect Effects 0.000 claims description 6
- 238000000799 fluorescence microscopy Methods 0.000 claims description 5
- 238000011534 incubation Methods 0.000 claims description 5
- 238000012546 transfer Methods 0.000 claims description 5
- 210000005253 yeast cell Anatomy 0.000 claims description 5
- 241000238631 Hexapoda Species 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 230000002538 fungal effect Effects 0.000 claims description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 231100000331 toxic Toxicity 0.000 claims description 3
- 231100000167 toxic agent Toxicity 0.000 claims description 3
- 239000003440 toxic substance Substances 0.000 claims description 3
- 238000003672 processing method Methods 0.000 claims description 2
- 102220054792 rs138065384 Human genes 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 abstract description 26
- 108060006633 protein kinase Proteins 0.000 abstract description 26
- 150000001875 compounds Chemical class 0.000 abstract description 16
- 230000001419 dependent effect Effects 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 abstract description 6
- 102220566687 GDNF family receptor alpha-1_F64L_mutation Human genes 0.000 abstract description 5
- 102220566469 GDNF family receptor alpha-1_S65T_mutation Human genes 0.000 abstract description 3
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 abstract description 3
- 108010085238 Actins Proteins 0.000 abstract description 2
- 102000007469 Actins Human genes 0.000 abstract description 2
- 102000040945 Transcription factor Human genes 0.000 abstract description 2
- 108091023040 Transcription factor Proteins 0.000 abstract description 2
- 230000002596 correlated effect Effects 0.000 abstract description 2
- -1 PKA Proteins 0.000 abstract 3
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 abstract 1
- 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 abstract 1
- 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 abstract 1
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 abstract 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 abstract 1
- 101100366888 Dictyostelium discoideum dstA gene Proteins 0.000 abstract 1
- 101000652725 Drosophila melanogaster Transcription initiation factor TFIID subunit 5 Proteins 0.000 abstract 1
- 102220566451 GDNF family receptor alpha-1_Y66H_mutation Human genes 0.000 abstract 1
- 101150033606 Grk5 gene Proteins 0.000 abstract 1
- 101000752722 Homo sapiens Apoptosis-stimulating of p53 protein 1 Proteins 0.000 abstract 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 abstract 1
- 101001120056 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit alpha Proteins 0.000 abstract 1
- 101001120097 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit beta Proteins 0.000 abstract 1
- 101001116549 Homo sapiens Protein CBFA2T2 Proteins 0.000 abstract 1
- 101001000998 Homo sapiens Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 abstract 1
- 101000927796 Homo sapiens Rho guanine nucleotide exchange factor 7 Proteins 0.000 abstract 1
- 101001046426 Homo sapiens cGMP-dependent protein kinase 1 Proteins 0.000 abstract 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
- 101150101215 Mapk8 gene Proteins 0.000 abstract 1
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 abstract 1
- 102000002001 Non-Receptor Type 6 Protein Tyrosine Phosphatase Human genes 0.000 abstract 1
- 108010015793 Non-Receptor Type 6 Protein Tyrosine Phosphatase Proteins 0.000 abstract 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 101710113459 RAC-alpha serine/threonine-protein kinase Proteins 0.000 abstract 1
- 101150111584 RHOA gene Proteins 0.000 abstract 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 102100021164 Vasodilator-stimulated phosphoprotein Human genes 0.000 abstract 1
- 230000004068 intracellular signaling Effects 0.000 abstract 1
- 239000003226 mitogen Substances 0.000 abstract 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 abstract 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 125000003607 serino group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 abstract 1
- 229960002898 threonine Drugs 0.000 abstract 1
- 108010054220 vasodilator-stimulated phosphoprotein Proteins 0.000 abstract 1
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 74
- 108090000623 proteins and genes Proteins 0.000 description 60
- 230000004927 fusion Effects 0.000 description 40
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 37
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 37
- 239000000523 sample Substances 0.000 description 37
- 102000004169 proteins and genes Human genes 0.000 description 31
- 108020001507 fusion proteins Proteins 0.000 description 20
- 102000037865 fusion proteins Human genes 0.000 description 20
- 238000011282 treatment Methods 0.000 description 20
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 16
- 238000003752 polymerase chain reaction Methods 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 230000019491 signal transduction Effects 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 150000007523 nucleic acids Chemical class 0.000 description 14
- 239000000872 buffer Substances 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 108010029485 Protein Isoforms Proteins 0.000 description 12
- 102000001708 Protein Isoforms Human genes 0.000 description 12
- 230000004807 localization Effects 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 108090000315 Protein Kinase C Proteins 0.000 description 11
- 102000003923 Protein Kinase C Human genes 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 238000011002 quantification Methods 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 238000010367 cloning Methods 0.000 description 9
- 230000001086 cytosolic effect Effects 0.000 description 9
- 210000004940 nucleus Anatomy 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 8
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 8
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 8
- 150000001982 diacylglycerols Chemical class 0.000 description 8
- 238000013459 approach Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000006525 intracellular process Effects 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 6
- 210000000805 cytoplasm Anatomy 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 239000007850 fluorescent dye Substances 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 102000051325 Glucagon Human genes 0.000 description 5
- 108060003199 Glucagon Proteins 0.000 description 5
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 5
- 102000030621 adenylate cyclase Human genes 0.000 description 5
- 108060000200 adenylate cyclase Proteins 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000036755 cellular response Effects 0.000 description 5
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 5
- 229960004666 glucagon Drugs 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 238000002821 scintillation proximity assay Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 description 4
- 108091006300 SLC2A4 Proteins 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 4
- 229960005263 bucladesine Drugs 0.000 description 4
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 4
- 229960004484 carbachol Drugs 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000006662 intracellular pathway Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 210000004292 cytoskeleton Anatomy 0.000 description 3
- 230000009849 deactivation Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000002073 fluorescence micrograph Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000004190 glucose uptake Effects 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 230000007398 protein translocation Effects 0.000 description 3
- 238000001454 recorded image Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- 108060003345 Adrenergic Receptor Proteins 0.000 description 2
- 102000017910 Adrenergic receptor Human genes 0.000 description 2
- 241000242764 Aequorea victoria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108010063919 Glucagon Receptors Proteins 0.000 description 2
- 102100040890 Glucagon receptor Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108010084455 Zeocin Proteins 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000030570 cellular localization Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 102000034287 fluorescent proteins Human genes 0.000 description 2
- 108091006047 fluorescent proteins Proteins 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 102000047882 human INSR Human genes 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 230000008054 signal transmission Effects 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000012144 step-by-step procedure Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000004960 subcellular localization Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 241000243290 Aequorea Species 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 239000010755 BS 2869 Class G Substances 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
- 102100023374 Forkhead box protein M1 Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108050002220 Green fluorescent protein, GFP Proteins 0.000 description 1
- 101000907578 Homo sapiens Forkhead box protein M1 Proteins 0.000 description 1
- 101001040075 Homo sapiens Glucagon receptor Proteins 0.000 description 1
- 101001051777 Homo sapiens Protein kinase C alpha type Proteins 0.000 description 1
- 101001026864 Homo sapiens Protein kinase C gamma type Proteins 0.000 description 1
- 101001087416 Homo sapiens Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 239000012820 MEK1 Inhibitor Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 102100024924 Protein kinase C alpha type Human genes 0.000 description 1
- 102100037314 Protein kinase C gamma type Human genes 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000592342 Tracheophyta Species 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 1
- 108091005971 Wild-type GFP Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 238000003705 background correction Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 102000043927 cAMP-dependent protein kinase catalytic subunit Human genes 0.000 description 1
- 108700038308 cAMP-dependent protein kinase catalytic subunit Proteins 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 210000001650 focal adhesion Anatomy 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000012804 iterative process Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 210000004492 nuclear pore Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 230000008560 physiological behavior Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000003478 prestimulatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 238000002777 redistribution assay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 210000003518 stress fiber Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000001954 time-lapse fluorescence microscopy Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
- G01N2333/43595—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from coelenteratae, e.g. medusae
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK39297 | 1997-04-07 | ||
| DK39297 | 1997-04-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69837118D1 DE69837118D1 (de) | 2007-03-29 |
| DE69837118T2 true DE69837118T2 (de) | 2007-12-27 |
Family
ID=8092994
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69837118T Expired - Fee Related DE69837118T2 (de) | 1997-04-07 | 1998-04-07 | Ein Verfahren zum Screenen von Substanzen hinsichtlich ihres Effekts auf cAMP Spiegel basierend auf intrazellulärer Translokation von PKA |
| DE1199564T Pending DE1199564T1 (de) | 1997-04-07 | 1998-04-07 | Verfahren zum Screenen von Substanzen die einen effekt auf intrazelluläre Translokation haben |
| DE69824763T Expired - Lifetime DE69824763T2 (de) | 1997-04-07 | 1998-04-07 | Verfahren zum Screenen von Substanzen die einen effekt auf intrazelluläre Translokation haben |
| DE69804446T Expired - Fee Related DE69804446T3 (de) | 1997-04-07 | 1998-04-07 | Verfahren um quantitativen informationen über einflüsse auf zelluläre reaktionen zu entnehmen |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE1199564T Pending DE1199564T1 (de) | 1997-04-07 | 1998-04-07 | Verfahren zum Screenen von Substanzen die einen effekt auf intrazelluläre Translokation haben |
| DE69824763T Expired - Lifetime DE69824763T2 (de) | 1997-04-07 | 1998-04-07 | Verfahren zum Screenen von Substanzen die einen effekt auf intrazelluläre Translokation haben |
| DE69804446T Expired - Fee Related DE69804446T3 (de) | 1997-04-07 | 1998-04-07 | Verfahren um quantitativen informationen über einflüsse auf zelluläre reaktionen zu entnehmen |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US6518021B1 (enExample) |
| EP (3) | EP1435519B1 (enExample) |
| JP (1) | JP2001522454A (enExample) |
| AT (3) | ATE354089T1 (enExample) |
| AU (1) | AU6820998A (enExample) |
| CA (1) | CA2286293C (enExample) |
| DE (4) | DE69837118T2 (enExample) |
| DK (2) | DK1435519T3 (enExample) |
| ES (2) | ES2191575T3 (enExample) |
| PT (2) | PT986753E (enExample) |
| WO (1) | WO1998045704A2 (enExample) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU226203B1 (en) | 1996-01-26 | 2008-06-30 | Virco B V B A | Method for determining of the chemotherapy of patients who are hiv positive based on the phenotypic drug sensitivity of human hiv strains |
| US7062219B2 (en) | 1997-01-31 | 2006-06-13 | Odyssey Thera Inc. | Protein fragment complementation assays for high-throughput and high-content screening |
| US6416959B1 (en) | 1997-02-27 | 2002-07-09 | Kenneth Giuliano | System for cell-based screening |
| US6759206B1 (en) | 1997-02-27 | 2004-07-06 | Cellomics, Inc. | System for cell-based screening |
| US7853411B2 (en) | 1997-02-27 | 2010-12-14 | Cellomics, Inc. | System for cell-based screening |
| WO1998045704A2 (en) * | 1997-04-07 | 1998-10-15 | Bioimage A/S | A method for extracting quantitative information relating to an influence on a cellular response |
| US7160687B1 (en) | 1997-05-29 | 2007-01-09 | Cellomics, Inc. | Miniaturized cell array methods and apparatus for cell-based screening |
| US6235512B1 (en) * | 1997-07-01 | 2001-05-22 | Tularik Inc. | IKK-α proteins, nucleic acids and methods |
| US20050221280A1 (en) | 1998-02-02 | 2005-10-06 | Odyssey Thera, Inc. | Protein-protein interactions for pharmacological profiling |
| US6388788B1 (en) | 1998-03-16 | 2002-05-14 | Praelux, Inc. | Method and apparatus for screening chemical compounds |
| US20030036855A1 (en) | 1998-03-16 | 2003-02-20 | Praelux Incorporated, A Corporation Of New Jersey | Method and apparatus for screening chemical compounds |
| AU765703B2 (en) * | 1998-03-27 | 2003-09-25 | Bruce J. Bryan | Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items |
| US6037133A (en) * | 1998-04-17 | 2000-03-14 | Clontech Laboratories, Inc. | IκBEGFP constructs, cell lines and methods of use |
| US6844315B2 (en) * | 1998-05-20 | 2005-01-18 | Erasmus Universiteit Rotterdam | Immunoregulator |
| US8680059B2 (en) * | 1998-05-20 | 2014-03-25 | Biotempt B.V. | Oligopeptide acetate and formulations thereof |
| US20030220258A1 (en) | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of ischemic events |
| AU6189999A (en) * | 1998-10-15 | 2000-05-08 | Bioimage A/S | Specific therapeutic interventions obtained by interference with redistribution and/or targetting |
| EP1121593A2 (en) * | 1998-10-15 | 2001-08-08 | BioImage A/S | Method for extracting quantitative information relating to an influence on a cellular response |
| GB9901072D0 (en) * | 1999-01-19 | 1999-03-10 | Imp Cancer Res Tech | Methods for detecting changes to a macromolecular component of a cell |
| JP3576491B2 (ja) * | 1999-02-26 | 2004-10-13 | セロミックス インコーポレイテッド | 細胞ベースのスクリーニング用のシステム |
| DE19915310A1 (de) * | 1999-04-03 | 2000-10-05 | Bayer Ag | Diffusionskontrollierende Sensorschicht |
| EP1048952B1 (en) * | 1999-04-29 | 2003-03-26 | Erasmus Universiteit Rotterdam | Determining analyte mobility |
| WO2000070528A2 (en) * | 1999-05-14 | 2000-11-23 | Cytokinetics, Inc. | Method and apparatus for predictive cellular bioinformatics |
| US6651008B1 (en) | 1999-05-14 | 2003-11-18 | Cytokinetics, Inc. | Database system including computer code for predictive cellular bioinformatics |
| US6743576B1 (en) | 1999-05-14 | 2004-06-01 | Cytokinetics, Inc. | Database system for predictive cellular bioinformatics |
| US7151847B2 (en) | 2001-02-20 | 2006-12-19 | Cytokinetics, Inc. | Image analysis of the golgi complex |
| US20030228565A1 (en) * | 2000-04-26 | 2003-12-11 | Cytokinetics, Inc. | Method and apparatus for predictive cellular bioinformatics |
| EP1055929A1 (en) * | 1999-05-26 | 2000-11-29 | Tibotec N.V. | Means and methods for drug discovery and the phenotypic characterisation of cells |
| US6573059B1 (en) * | 1999-06-04 | 2003-06-03 | Rmf Dictagene S.A. | Use of the regulatory subunit of the camp dependent protein kinase (PKA) from dictyostelium for camp measurements |
| EP1101113A4 (en) * | 1999-06-09 | 2002-05-08 | Ljl Biosystems Inc | CELL SIGNALING TESTS |
| US6673554B1 (en) | 1999-06-14 | 2004-01-06 | Trellie Bioinformatics, Inc. | Protein localization assays for toxicity and antidotes thereto |
| AU7131900A (en) * | 1999-06-21 | 2001-01-09 | Cellomics, Inc. | A system for cell-based screening |
| US6121047A (en) * | 1999-07-21 | 2000-09-19 | Isis Pharmaceuticals Inc. | Antisense modulation of SHP-1 expression |
| US6489151B1 (en) * | 2000-03-27 | 2002-12-03 | The Research Foundation Of State University Of New York | Biologically active alternative form of the IKKα IκB kinase |
| EP1300418A1 (en) * | 2001-10-04 | 2003-04-09 | Erasmus Universiteit Rotterdam | Gene regulation by oligopeptides |
| KR100414641B1 (ko) * | 2000-04-07 | 2004-01-13 | 동부한농화학 주식회사 | 형질전환식물체의 생체분석방법 및 그를 이용한 시스템 |
| EP1276897A2 (en) * | 2000-04-17 | 2003-01-22 | BioImage A/S | Live cell procedures to identify compounds modulating intracellular distribution of phosphodiesterase (pde) enzymes |
| US20030162165A1 (en) * | 2000-04-26 | 2003-08-28 | Arkhammer Per O.G. | Chemical signal enhancement of dynamic intensity-based intracellular protein-and fluorophore-based redistribution assays for drug-screening |
| US20020049544A1 (en) * | 2000-06-23 | 2002-04-25 | Cytokinetics, Inc. | Image analysis for phenotyping sets of mutant cells |
| JP2004502434A (ja) | 2000-07-04 | 2004-01-29 | バイオイメージ エイ／エス | 細胞成分間の相互作用に関する量的情報の抽出方法 |
| US7625951B2 (en) | 2000-07-13 | 2009-12-01 | University Of Kentucky Research Foundation | Stimuli-responsive hydrogel microdomes integrated with genetically engineered proteins for high-throughput screening of pharmaceuticals |
| DE10037759A1 (de) * | 2000-08-03 | 2002-07-04 | Gruenenthal Gmbh | Screeningverfahren |
| KR100414781B1 (ko) * | 2000-11-24 | 2004-01-13 | 재단법인서울대학교산학협력재단 | ＮＦ-κＢ 발현을 인간 피부세포에서 정량적으로 측정하기위한 안정한 분석시스템 및 그의 용도 |
| US7218764B2 (en) | 2000-12-04 | 2007-05-15 | Cytokinetics, Inc. | Ploidy classification method |
| US6956961B2 (en) | 2001-02-20 | 2005-10-18 | Cytokinetics, Inc. | Extracting shape information contained in cell images |
| US7016787B2 (en) | 2001-02-20 | 2006-03-21 | Cytokinetics, Inc. | Characterizing biological stimuli by response curves |
| US7033790B2 (en) | 2001-04-03 | 2006-04-25 | Curagen Corporation | Proteins and nucleic acids encoding same |
| EP1499885B1 (en) | 2001-08-01 | 2009-10-21 | Cellomics, Inc. | Novel fusion proteins and assays for molecular binding |
| AU2002358657A1 (en) * | 2001-12-10 | 2003-06-23 | Evotec Oai Ag | Method for determining the influence of non-physiological compounds the derivatives and decomposition products thereof on organisms organs and cells |
| US7176303B2 (en) * | 2003-11-06 | 2007-02-13 | Isis Pharmaceuticals, Inc. | Modulation of STAT5 expression |
| US20080318871A1 (en) * | 2001-12-21 | 2008-12-25 | Khan Nisar A | Treatment of neurological disorders |
| US20030220257A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of trauma |
| US20080242837A1 (en) * | 2001-12-21 | 2008-10-02 | Khan Nisar A | Peptide compositions |
| US7560433B2 (en) | 2001-12-21 | 2009-07-14 | Biotempt B.V. | Treatment of multiple sclerosis (MS) |
| US7786084B2 (en) * | 2001-12-21 | 2010-08-31 | Biotempt B.V. | Treatment of burns |
| CA2413475C (en) | 2002-04-25 | 2010-07-27 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Zap-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll) |
| GB0216674D0 (en) * | 2002-07-18 | 2002-08-28 | Amersham Biosciences Uk Ltd | Functional screening method |
| US8168568B1 (en) | 2003-03-10 | 2012-05-01 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Combinatorial therapy for protein signaling diseases |
| GB2423988A (en) | 2003-07-18 | 2006-09-13 | Cytokinetics Inc | Characterizing biological stimuli by response curves |
| US20050014217A1 (en) | 2003-07-18 | 2005-01-20 | Cytokinetics, Inc. | Predicting hepatotoxicity using cell based assays |
| US7235353B2 (en) | 2003-07-18 | 2007-06-26 | Cytokinetics, Inc. | Predicting hepatotoxicity using cell based assays |
| US20050060100A1 (en) * | 2003-09-15 | 2005-03-17 | Becton Dickinson And Company | Computer software and algorithms for systems biologically linked to cellular phenotype |
| US20050059083A1 (en) * | 2003-09-15 | 2005-03-17 | Becton Dickinson And Company | High throughput method to identify ligands for cell attachment |
| US20090227505A1 (en) * | 2004-01-07 | 2009-09-10 | Biotempt B.V. | Methods and uses for protein breakdown products |
| US8586294B2 (en) | 2004-05-18 | 2013-11-19 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of protein translocation by beta-galactosidase reporter fragment complementation |
| US7323318B2 (en) | 2004-07-15 | 2008-01-29 | Cytokinetics, Inc. | Assay for distinguishing live and dead cells |
| US8084260B2 (en) * | 2004-11-24 | 2011-12-27 | Applied Biosystems, Llc | Spectral calibration method and system for multiple instruments |
| WO2007004869A2 (en) * | 2005-07-05 | 2007-01-11 | Biotempt B.V. | Treatment of tumors |
| US20080227131A1 (en) * | 2005-10-28 | 2008-09-18 | Ge Healthcare Uk Limited | Signalling Assay and Cell Line |
| US20090170091A1 (en) * | 2006-01-17 | 2009-07-02 | Kenneth Giuliano | Method For Predicting Biological Systems Responses |
| EP1864692A1 (en) * | 2006-06-07 | 2007-12-12 | Biotempt B.V. | Use of peptides for the control of radiation injury |
| CN101484806A (zh) | 2006-05-17 | 2009-07-15 | 协乐民公司 | 一种对组织进行自动分析的方法 |
| EP2095119A2 (en) * | 2006-11-10 | 2009-09-02 | Cellumen, Inc. | Protein-protein interaction biosensors and methods of use thereof |
| US20100178652A1 (en) * | 2007-01-05 | 2010-07-15 | Litherland Sally A | Materials and Methods for the Detection, Prevention and Treatment of Autoimmune Disease |
| DK2120991T3 (da) * | 2007-02-12 | 2014-04-28 | Biotempt Bv | Behandling af traumatisk blødning med korte oligopeptider |
| US20080217002A1 (en) * | 2007-03-07 | 2008-09-11 | Floyd Randolph Simonds | Sand control screen having a micro-perforated filtration layer |
| JP5438962B2 (ja) * | 2008-12-25 | 2014-03-12 | シスメックス株式会社 | 細胞画像表示装置 |
| WO2010078290A2 (en) * | 2008-12-29 | 2010-07-08 | President And Fellows Of Harvard College | System for screening agonists/antagonists of cellular signaling pathways |
| KR101088605B1 (ko) | 2009-06-30 | 2011-11-30 | 한국산업기술대학교산학협력단 | 2대의 카메라를 이용한 세포 조작 방법 |
| JP5089713B2 (ja) * | 2010-01-18 | 2012-12-05 | シャープ株式会社 | 画像圧縮装置、圧縮画像出力装置、画像圧縮方法、コンピュータプログラム及び記録媒体 |
| ES2739623T3 (es) | 2011-03-17 | 2020-02-03 | Cernostics Inc | Sistemas y composiciones para diagnosticar el esófago de Barrett y métodos para usarlos |
| WO2013138684A1 (en) | 2012-03-15 | 2013-09-19 | Montana Molecular Llc | Genetically encoded fluorescent sensors for detecting intracellular signalling through diacylglycerol pathways |
| EP2682187B1 (en) * | 2012-07-02 | 2017-09-13 | Molecular Devices, LLC | Selection method and apparatus |
| EP3738971B1 (en) | 2013-11-04 | 2024-07-17 | Montana Molecular LLC | Genetically encoded fluorescent sensors for detecting ligand bias and intracellular signaling through camp pathways |
| DE102014012130B3 (de) | 2014-08-13 | 2015-03-05 | Alfred-Wegener-Institut, Helmholtz-Zentrum für Polar- und Meeresforschung | Nachweisverfahren unter Verwendung von rekombinanten lebenden Zellen zum Nachweis von xenobiotischen Stoffen sowie Anordnung und Testkit zur Durchführung des Nachweisverfahrens |
| WO2022146025A1 (ko) * | 2020-12-30 | 2022-07-07 | 한국과학기술원 | 암전이 억제 및 항암제 감수성 증진용 조성물 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT321257B (de) | 1971-05-26 | 1975-03-25 | Koreska Gmbh W | Anlage zur Rückgewinnung flüchtiger Lösungsmittel |
| JPS57198544A (en) | 1981-05-28 | 1982-12-06 | Sony Corp | Manufacture of magnetic recording medium |
| DE3240063A1 (de) | 1981-11-02 | 1983-05-26 | Basf Ag, 6700 Ludwigshafen | Vorrichtung zur herstellung eines magnetogrammtraegers |
| JPS5880136A (ja) | 1981-11-02 | 1983-05-14 | Fuji Photo Film Co Ltd | 磁気記録材料の製造方法 |
| JPH0656656B2 (ja) | 1983-10-03 | 1994-07-27 | 富士写真フイルム株式会社 | 磁気記録媒体の製造方法 |
| JPS6292132A (ja) | 1985-10-18 | 1987-04-27 | Fuji Photo Film Co Ltd | 磁気記録媒体の製造方法 |
| US4923766A (en) | 1988-03-29 | 1990-05-08 | Canon Kabushiki Kaisha | Process for preparing magnetic recording |
| GB8916806D0 (en) * | 1989-07-22 | 1989-09-06 | Univ Wales Medicine | Modified proteins |
| DE4009797A1 (de) | 1990-03-27 | 1991-10-02 | Pagendarm Gmbh | Verfahren und anordnung zum kondensieren von dampffoermigen substanzen |
| WO1994023039A1 (en) * | 1993-04-07 | 1994-10-13 | The Institute Of Cancer Research: Royal Cancer Hospital | Methods for screening of substances for therapeutic activity and yeast for use therein |
| CA2169298A1 (en) * | 1993-09-10 | 1995-03-16 | Martin Chalfie | Uses of green fluorescent protein |
| JP4215274B2 (ja) * | 1994-07-22 | 2009-01-28 | ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル | Ｓｒｃ ＳＨ３結合性ペプチドとその分離法と利用法 |
| US6184205B1 (en) * | 1994-07-22 | 2001-02-06 | University Of North Carolina At Chapel Hill | GRB2 SH3 binding peptides and methods of isolating and using same |
| US5874231A (en) * | 1994-08-22 | 1999-02-23 | Mcgill University | Methods of screening for non-hormone compounds which effect modulation of polypeptide translation |
| US5958713A (en) | 1995-01-31 | 1999-09-28 | Novo Nordisk A/S | Method of detecting biologically active substances by using green fluorescent protein |
| ATE211506T1 (de) * | 1995-01-31 | 2002-01-15 | Bioimage As | Ein verfahren zum nachweis biologisch aktiver substanzen |
| DE69604298T2 (de) * | 1995-09-22 | 2000-05-18 | Bioimage A/S, Soeborg | Varianten des grünen fluoreszenzproteins, gfp |
| CA2239951A1 (en) * | 1995-12-08 | 1997-06-12 | The Government Of The United States, Represented By The Secretary, Depar Tment Of Health And Human Services | Method and compositions for monitoring dna binding molecules in living cells |
| US5874304A (en) * | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| US5989835A (en) * | 1997-02-27 | 1999-11-23 | Cellomics, Inc. | System for cell-based screening |
| AU3801997A (en) * | 1996-07-16 | 1998-02-09 | Regents Of The University Of California, The | Assays for protein kinases using fluorescent protein substrates |
| AU5090498A (en) * | 1997-01-07 | 1998-08-03 | California Institute Of Technology | Optical sensors of cell signaling |
| DE69839501D1 (de) * | 1997-02-27 | 2008-06-26 | Cellomics Inc | System für Screening biologischer Zellen |
| US6416959B1 (en) * | 1997-02-27 | 2002-07-09 | Kenneth Giuliano | System for cell-based screening |
| WO1998045704A2 (en) * | 1997-04-07 | 1998-10-15 | Bioimage A/S | A method for extracting quantitative information relating to an influence on a cellular response |
| WO2000049183A1 (en) * | 1999-02-17 | 2000-08-24 | Clontech Laboratories, Inc. | FLUORESCENCE RESONANCE ENERGY TRANSFER DETECTION OF cAMP IN LIVING CELLS USING GFP VARIANTS |
| US6573059B1 (en) * | 1999-06-04 | 2003-06-03 | Rmf Dictagene S.A. | Use of the regulatory subunit of the camp dependent protein kinase (PKA) from dictyostelium for camp measurements |
-
1998
- 1998-04-07 WO PCT/DK1998/000145 patent/WO1998045704A2/en not_active Ceased
- 1998-04-07 DE DE69837118T patent/DE69837118T2/de not_active Expired - Fee Related
- 1998-04-07 ES ES01204477T patent/ES2191575T3/es not_active Expired - Lifetime
- 1998-04-07 PT PT98913541T patent/PT986753E/pt unknown
- 1998-04-07 CA CA002286293A patent/CA2286293C/en not_active Expired - Lifetime
- 1998-04-07 DK DK03028919T patent/DK1435519T3/da active
- 1998-04-07 DE DE1199564T patent/DE1199564T1/de active Pending
- 1998-04-07 AT AT03028919T patent/ATE354089T1/de not_active IP Right Cessation
- 1998-04-07 EP EP03028919A patent/EP1435519B1/en not_active Expired - Lifetime
- 1998-04-07 JP JP54227698A patent/JP2001522454A/ja active Pending
- 1998-04-07 AT AT98913541T patent/ATE215227T1/de not_active IP Right Cessation
- 1998-04-07 AU AU68209/98A patent/AU6820998A/en not_active Abandoned
- 1998-04-07 DE DE69824763T patent/DE69824763T2/de not_active Expired - Lifetime
- 1998-04-07 AT AT01204477T patent/ATE269975T1/de not_active IP Right Cessation
- 1998-04-07 EP EP01204477A patent/EP1199564B1/en not_active Expired - Lifetime
- 1998-04-07 ES ES98913541T patent/ES2173573T5/es not_active Expired - Lifetime
- 1998-04-07 DE DE69804446T patent/DE69804446T3/de not_active Expired - Fee Related
- 1998-04-07 EP EP98913541A patent/EP0986753B2/en not_active Expired - Lifetime
- 1998-04-07 PT PT01204477T patent/PT1199564E/pt unknown
- 1998-04-07 DK DK98913541T patent/DK0986753T4/da active
-
1999
- 1999-10-07 US US09/417,197 patent/US6518021B1/en not_active Expired - Lifetime
-
2002
- 2002-02-05 US US10/072,036 patent/US8058008B2/en not_active Expired - Fee Related
-
2007
- 2007-10-29 US US11/927,246 patent/US20090023598A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69804446T3 (de) | Verfahren um quantitativen informationen über einflüsse auf zelluläre reaktionen zu entnehmen | |
| DE60002562T2 (de) | Ein system für zellbasierte reihenuntersuchungen | |
| DE60023905T2 (de) | Optische Systemanalyse von Zellen | |
| DE69824174T2 (de) | Ein system zur zellbasierten reihenuntersuchung | |
| Bozza et al. | In vivo imaging of neuronal activity by targeted expression of a genetically encoded probe in the mouse | |
| Ouyang et al. | Visualization of the distribution of autophosphorylated calcium/calmodulin-dependent protein kinase II after tetanic stimulation in the CA1 area of the hippocampus | |
| DE69905049T2 (de) | Auf zellen basiertes screening-system | |
| US7282347B2 (en) | Method for extracting quantitative information relating to interactions between cellular components | |
| MXPA01010175A (es) | Metodo de tamizado de compuestos.. | |
| EP1644733B1 (en) | Screening methods employing zebrafish and the blood brain barrier | |
| Seidenthal et al. | Flower/FLWR-1 regulates neuronal activity via the plasma membrane Ca2+ ATPase to promote recycling of synaptic vesicles | |
| EP1121593A2 (en) | Method for extracting quantitative information relating to an influence on a cellular response | |
| Wayne et al. | Whole-cell electrophysiology of gonadotropin-releasing hormone neurons that express green fluorescent protein in the terminal nerve of transgenic medaka (Oryzias latipes) | |
| Sugai et al. | Novel subdivisions of the rat accessory olfactory bulb revealed by the combined method with lectin histochemistry, electrophysiological and optical recordings | |
| DE60225168T2 (de) | Verfahren zur auswahl bioaktiver wirkstoffe durch lumineszenzkopplung und lebendes zellensystem dafür | |
| Austin et al. | Lampbrush chromosomes enable study of cohesin dynamics | |
| KR102234421B1 (ko) | eGRASP를 이용한 세포 사이의 인접 표지 기술 | |
| DE602004013320T2 (de) | Verfahren zur demonstration eines molekularen ereignisses in einer zelle mittels fluoreszenzmarkerproteinen | |
| Cuentas-Condori et al. | Imaging dendritic spines in Caenorhabditis elegans | |
| Fletcher et al. | Ganglion cell assessment in rodents with retinal degeneration | |
| Leiss | Dendritic spines and structural plasticity in Drosophila | |
| DE102006000942A1 (de) | Adenylat-Zyklase, für die Adenylat-Zyklase kodierende Gensequenz, Vektoren und Zellen sowie deren Verwendung | |
| Wang et al. | RETRACTED | |
| CA2450698A1 (en) | A method for screening substances for effect on camp levels based on intracellular translocation of pka |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |